49 下列帕金森氏症（Parkinson’s disease）的治療藥品中，何者的主要作用並非藉由抑制周邊 dopamine的代謝作用而達治療目的？
(A) Benserazide
(B) Carbidopa
(C) Entacapone
(D) Ropinirole

答案：登入後查看
統計： A(43), B(48), C(50), D(446), E(0) #412588

詳解 (共 7 筆)

#2292152

Ropinirole 是 非麥角類D2, D3 agonist

9
0
#2915616

Benserazide 和 Carbidopa 是抑制周邊的L-DOPA代謝

7
0
#3184916

Entacapone是COMT inhibitor

5
0
#820915
Benserazide (also called Serazide or Ro 4-4602) is a peripherally-acting aromatic L-amino acid decarboxylase (AADC) or DOPA decarboxylase inhibitor, which is unable to cross the blood–brain barrier.
3
0
#820921
Benserazide An l-aromatic amino acid decarboxylase (dopa decarboxylase) inhibitor resembling carbidopa in action; given in combination with levodopa as an antiparkinsonian regimen. The benserazide prevents peripheral destruction of levodopa and thus reduces cardiovascular side effects of treatment.
2
0
#5541001

增加DA合成 : 

DA Pro-drug Levodopa(在腦中轉變為DA作用)

抑制DA代謝 : 

抑制周邊Decarboxylase Carbidopa；Benserazide
COMT Entacapone；Tolcapone
不可逆抑制中樞MAO-B Seligiline；Rasagiline
1
0
#5692999
Ropinirole ：非麥角衍生物，為...
(共 45 字，隱藏中）
前往觀看
0
0